source
- Genentech signs $1.5 billion bispecific antibody deal with Earendil LabsGenentech, Roche's US subsidiary, announced a licensing agreement with Earendil Labs to discover and develop multiple bispecific antibodies aimed at oncology. The agreement provides a $55 million…
- ADARx upsizes Nasdaq IPO to $446M as City Therapeutics eyes public listingADARx Pharmaceuticals, a San Diego-based RNA biotech, completed a Nasdaq initial public offering this morning, selling 26.3 million shares at $17 each. The offering generated gross proceeds of abo…